|
| Status |
Public on Feb 05, 2013 |
| Title |
DHT+Dex rep 3 |
| Sample type |
RNA |
| |
|
| Source name |
LNCaP-1F5 cell line
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: LNCaP-1F5
treatment: DHT+Dex
|
| Treatment protocol |
LNCaP-1F5 cells were grown in charcoal stripped medium for 3 days followed by treated with vehicle or 100 nM DHT or 100 nM Dex or 1000 nM CPA or 1000 nM (RU486) or combination of 100 nM DHT+Dex for 24 hours followed by RNA isolation.
|
| Growth protocol |
LNCaP-1F5 cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 10 mM HEPES supplemented with antibiotics (penicillin and streptomycin).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted with QIAGEN RNeasy mini kitwith DNaseI treatment in accordance with the prescribed protocol provided with the kit. Quality control was performed with Agilent Bioanalyser.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Description |
replicate 3 treated with DHT+Dex for 24 hours
5298416049_L
|
| Data processing |
The data were normalised using quantile normalisation with BeadStudio Program from Illumina.
|
| |
|
| Submission date |
Jul 25, 2012 |
| Last update date |
Feb 05, 2013 |
| Contact name |
Olli A. Jänne |
| E-mail(s) |
olli.janne@helsinki.fi
|
| Phone |
+358919125040
|
| Organization name |
University of Helsinki
|
| Department |
Inst. of Biomedicine/Physiology
|
| Lab |
Androgen Receptor Laboratory
|
| Street address |
Haartmaninkatu-8
|
| City |
Helsinki |
| ZIP/Postal code |
FI-00014 |
| Country |
Finland |
| |
|
| Platform ID |
GPL6947 |
| Series (2) |
| GSE39654 |
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells (mRNA) |
| GSE39880 |
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells |
|
